Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | F12 | P00748 | 4/20 | 0.41 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.40 |
| ▸ | PRLHR | P49683 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328851 | 0.89 | F12 (0.43) | F12MTHFD2PDE10A | |
| SCHEMBL13328897 | 0.88 | CCR5 (0.44) | CYP2D6CYP2C9CYP3A4CYP2C19F12 | |
| SCHEMBL14046797 | 0.81 | MAPT (0.44) | CYP2D6CYP2C9CYP2C19MTHFD2CYP1A2 | |
| SCHEMBL13250275 | 0.81 | PTGDR2 (0.40) | F12 | |
| SCHEMBL13250046 | 0.81 | PARP1 (0.47) | F12 | |
| SCHEMBL13249785 | 0.80 | CYP2D6 (0.43) | CYP2D6CYP2C9CYP3A4CYP2C19F12 | |
| SCHEMBL13328898 | 0.79 | TSHR (0.45) | MTHFD2TSHRCCR5 | |
| SCHEMBL14046931 | 0.78 | F12 (0.40) | F12PDE10A | |
| SCHEMBL13329665 | 0.78 | F12 (0.40) | F12PDE10A | |
| SCHEMBL13328913 | 0.78 | MGLL (0.47) | CYP2D6CYP2C9CYP3A4CYP2C19MTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | CYP2D6 2170/4885CYP2C9 1570/4885CYP3A4 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.